CoinVoice has learned that Hanyu Pharmaceutical (300199.SZ) surged to its daily limit in the afternoon, quoting 24.32 yuan, with the stock price reaching a new high since December 2022.
It has been learned that Hanyu Pharmaceutical and the digital asset platform KuCoin have officially signed a strategic cooperation intention letter, with both parties intending to jointly explore the first RWA (Real World Asset) tokenization pilot project in mainland China, based on 'future revenue rights of innovative drug R&D' as the underlying asset in Hong Kong.
According to the agreement, Hanyu Pharmaceutical will use its technical accumulation and R&D pipeline in the GLP-1 class peptide blockbuster drug field as the underlying asset, while KuCoin will leverage its advantages in blockchain technology, RWA full-process solutions, and global compliance resources to provide integrated support for the project, including on-chain mapping, asset tokenization, transaction matching, and profit distribution. (Gelonghui) [Original link]